Open AccessUltrasound in evaluating ovarian reserve, is it reliable?
Author(s) -
Eman Ahmaed Shawky Sabek,
Ola I Saleh,
H.A. Ahmed
Publication year - 2015
Publication title -
the egyptian journal of radiology and nuclear medicine /the egyptian journal of radiology and nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 13
eISSN - 2090-4762
pISSN - 0378-603X
DOI - 10.1016/j.ejrnm.2015.08.008
Subject(s) - antral follicle , ovarian reserve , medicine , follicular phase , transvaginal ultrasound , hormone , gynecology , ultrasound , urology , chemotherapy , ovarian cancer , radiology , cancer , biology , pregnancy , infertility , genetics
The objective of this study was to compare the diagnostic accuracy of transvaginal ultrasound (TVS), as a less invasive technique instead of hormonal assay to evaluate the ovarian reserve. This study included fifty-five females with breast cancer and we compared the ovarian reserve for these patients by hormonal assay through measuring the serum AntiMullerian Hormone (AMH) level and follicular stimulating hormone (FSH) level before and after chemotherapy, and by transvaginal ultrasound through the ovarian volume (OV) calculation and counting the Antral follicles (AFC) before and after chemotherapy treatment. There was decline in the AntiMullerian Hormone level after chemotherapy by 27 ± 11.19% and decrease in the Antral follicle counts by 21 ± 13.43%. In conclusion there was strong relation between AMH level and AFC which makes the use of transvaginal ultrasound is a reliable alternative method to the hormonal assay to detect the ovarian reserve